Introduction {#Sec1}
============

The World Health Organization's Eastern Mediterranean Region (EMR) is an administrative region of 22 countries (Table [1](#Tab1){ref-type="table"}) that while rich in natural resources, has marked country-level variation in socioeconomic wealth (ranging from \$US 549.3 per capita in Somalia to \$US 73,653.4 per capita in Qatar), health system capacities and health coverage (Blair et al. [@CR2]; Mandil et al. [@CR15]; WHO [@CR31]). Many countries in the EMR have recently experienced social and political instabilities, civil unrest, war, and mass displacement of people (Mokdad et al. [@CR18]). As a result, health in many EMR countries has failed to improve in recent years (Mokdad et al. [@CR18], [@CR17]). As other papers in this series highlight, there is now an increasing burden of many preventable health problems including HIV, mental health disorders, and intentional injury (GBD 2015 Eastern Mediterranean Region HIV/AIDS Collaborators and Mokdad [@CR7]; GBD 2015 Eastern Mediterranean Region Intentional Injuries Collaborators and Mokdad [@CR8]; GBD 2015 Eastern Mediterranean Region Mental Health Collaborators and Mokdad [@CR9]). There is a risk that without urgent action, the health status of this region will only deteriorate further, with both regional and global consequences for health, social stability, and economic development.Table 1Eastern Mediterranean region: Countries, adolescent population and socioeconomic development, 1990--2015 (World Bank, Global Burden of Disease Study 2015, Eastern Mediterranean Countries, 1990--2015)CountryProportion of country population aged 10--24 year in % (*n*, number of adolescents in each country)Proportion of the EMR adolescent population (%)GDP per capita (\$US)Socio-demographic index (SDI)19902015SDI levelAfghanistan34.8% (11,356,556)6.2594.30.14400.2888LowBahrain21.7% (296,971)0.222,600.20.59690.7764High-middleDjibouti30.5% (271,064)0.11945.10.32280.4615Low-middleEgypt26.9% (24,492,800)13.33614.70.44090.6191MiddleIran22.8% (17,992,150)9.8--0.46000.7154High-middleIraq31.2% (11,348,292)6.24943.80.39970.5756MiddleJordan29.9% (2,263,213)1.24940.00.49670.6949High-middleKuwait19.1% (745,077)0.429,300.60.69110.8624HighLebanon28.5% (1,643,663)0.98047.60.56980.7547High-middleLibya25.0% (1,574,514)0.9--0.47470.6430MiddleMorocco26.0% (8,932,361)4.82878.20.33470.4959Low-middleOman21.4% (960,174)0.515,550.70.40890.7301High-middlePakistan30.2% (57,088,761)311434.70.27860.4676Low-middlePalestine33.6% (1,569,806)0.9--0.42290.5670MiddleQatar19.3% (429,261)0.273,653.40.61620.8045High-middleSaudi Arabia24.4% (7,683,094)4.220,481.70.52450.7593High-middleSomalia32.7% (3,545,571)1.9549.30.11580.1506LowSudan32.1% (12,950,382)7.02414.70.26670.4282Low-middleSyria32.4% (6,032,616)3.3--0.38810.5790MiddleTunisia22.6% (2,546,994)1.43872.50.45030.6515MiddleUnited Arab Emirates16.6% (1,516,072)0.840,438.80.63240.8747HighYemen34.2% (9,191,689)5.01406.30.13290.4080Low-middleTotal28.4% (184,431,081)100--------This table details the 22 countries in the East Mediterranean region. It provides the population of adolescents and contribution of each country to the total adolescent population in the Eastern Mediterranean Region. It also provides the overall country-level GDP in 2015 and SDI in 1990 and 2015. Dashes indicate data are unavailable

Adolescence is increasingly understood as a key developmental stage for assuring health across the course of one's life, and as such, provides significant opportunities to improve population health in the EMR (Patton et al. [@CR21]; The World Bank [@CR24]). Firstly, adolescents represent more than a quarter of the population in the EMR, and their health needs are likely to be distinct from children and adults. Conflict and civil unrest (which have been a feature of many countries in the EMR) have a large impact on the health of young people, both acutely (through high rates of mortality and morbidity due to violence) but also in the longer term (including mental health disorder and poor sexual and reproductive health) (Viner et al. [@CR29]). Secondly, many health risks typically emerge during adolescence including those for non-communicable diseases (NCDs) such as substance use, overweight, and physical inactivity. Given that NCDs are now the leading cause of poor health in the EMR, there is a potential to intervene before harms arise (Mokdad et al. [@CR19]). Thirdly, adolescents are critical to driving socioeconomic development (The World Bank [@CR24]). Poor physical health and mental health are barriers to participation in education and employment, as are policies and systems that do not enable equitable access. Finally, in their role as current and future parents, the health of adolescents has significant implications for the next generation (Patton et al. [@CR21]).

To date, the health problems and health risks of adolescents in the EMR have been inadequately described (Alaovie et al. [@CR1]). This is a significant barrier to developing comprehensive policies that address adolescent health and to measuring the impact of any investments made. This paper aims to report the health profile for adolescents living in the EMR.

Methods {#Sec2}
=======

We framed our study around the conceptual framework defined by the Lancet Commission of Adolescent Health and Wellbeing (hereafter referred to as the Commission) (Patton et al. [@CR21]). Health needs included: health outcomes (mortality, non-fatal diseases, and injuries); health risks (behaviors and states that carry risk for poor health in and beyond adolescence); and determinants of health (such as education and employment). Adolescence was defined as 10--24 years, as these years encompass the important biological, neurocognitive, and social role transitions that typically define adolescence (Mokdad et al. [@CR19]; Patton et al. [@CR21]; Sawyer et al. [@CR22]). Where possible, we report age-disaggregated data for young adolescents (10--14 years), older adolescents (15--19 years), and young adults (20--24 years) (Patton et al. [@CR21]).

Data are drawn from the Global Burden of Disease Study 2015 (GBD 2015) as this provides a complete set of comparable health estimates for 195 countries, including all those in the EMR. Methods are described in detail elsewhere (GBD DALYs Hale Collaborators [@CR10]; GBD Disease Injury Incidence and Prevalence Collaborators [@CR11]; GBD Mortality and Causes of Death Collaborators [@CR12]; GBD SDG Collaborators [@CR13]), but briefly, GBD 2015 includes a comprehensive and systematic analysis of 249 causes of death, 310 causes of disease and injury, and 79 behavioral and environmental health risks. GBD 2015 has four levels of causes that are mutually exclusive. Level one has three causes: type I conditions (communicable, maternal, neonatal, and nutritional disorders); non-communicable diseases; and injuries. Level two has 21 causes, while levels three and four consist of all disaggregated causes. For this analysis we report causes at level four. GBD is based on the best available primary data and employs a series of disease models to harmonize health estimates and fill data gaps. Each step of the estimation process of GBD 2015 has been documented, as well as data sources, in accordance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). For this analysis, we accessed data in 5-year age bands, for males and females, from 1990 to 2015 in 5-year time slices.

Mortality is reported as all-cause and cause-specific rates per 100,000 (GBD Mortality and Causes of Death Collaborators [@CR12]). Non-fatal diseases and injuries are reported as years lived with disability (YLDs), a metric which incorporates prevalence of disease, duration, and its severity (using disease weights) (GBD Disease Injury Incidence and Prevalence Collaborators [@CR11]). As a summary measure of population health, we also report disability-adjusted life-years (DALYs), the sum of years of healthy life lost due to premature mortality (YLLs), and years of life lived with disability (YLDs) (GBD DALYs Hale Collaborators [@CR10]). For these estimates, we report 95% uncertainty estimates, which are distinct from confidence intervals in that they represent uncertainty derived from sampling, model estimation, and model specification (GBD DALYs Hale Collaborators [@CR10]).

In addition to region-level estimates, we also report country-specific DALY estimates and the prevalence of three key health risks and four determinants (aligned with the conceptual framework from the Commission and data availability) to help prioritize country-specific actions (Patton et al. [@CR21]). Data for health risks were sourced from GBD 2015. Tobacco smoking was defined as current daily smoked tobacco use (GBD Tobacco Collaborators [@CR14]). Overweight was defined using the International Obesity Task Force age and gender specific cut-offs, equivalent to BMI ≥25 kg/m^2^ at age 18 (Cole and Lobstein [@CR3]). This definition includes those who are obese. Binge drinking was defined as having consumed 60 grams of alcohol on a single occasion for males and 48 grams of alcohol on a single occasion for females in the last 12 months. With respect to determinants, adolescent fertility rate (live births per 1000 15- to 19-year-old females) and mean years of educational attainment for 15- to 24-year olds were sourced from GBD 2015 (GBD SDG Collaborators [@CR13]). Unmet need for contraception (15- to 24-year-old females currently married or in union and not wanting to become pregnant within the next two years, who report not using any method of contraception) was sourced from a review DHS and MICS surveys available in the EMR (data were collected from 2009 to 2014) (Patton et al. [@CR21]). Youth unemployment data, defined as the percentage of 15- to 24-year olds without work but available for and seeking employment, were obtained from the International Labor Organization modeled estimates for 2013 (Patton et al. [@CR21]).

We reported observed estimates for the region. We additionally report *expected* DALYs for each country based on the level of socioeconomic development. Expected DALYs were estimated using the Socio-demographic Index (SDI) which is based on income per capita, average educational attainment for ages 15 or older, and the total fertility rate (GBD SDG Collaborators [@CR13]). SDI is reported as a continuous variable from 0 (lowest) to 1 (highest), and as quintiles, as shown in Table [1](#Tab1){ref-type="table"}. GBD 2015 has estimated the relationship between SDI and each cause of DALYs using spline regressions, with these regressions then used to estimate expected DALYs at each level of SDI (GBD DALYs Hale Collaborators [@CR10]).

Results {#Sec3}
=======

Mortality {#Sec4}
---------

All-cause mortality rates for adolescents in the EMR ranged from 63.3 per 100,000 for females aged 10--14 years to 253.2 per 100,000 for males aged 20--24 years in 2015 (e-Figure 1, panel A). Males had a higher overall mortality rate than females. The risk of mortality for males aged 15--24 years had increased over recent years compared to what was otherwise an overall trend of reduction in mortality. Table [2](#Tab2){ref-type="table"} details the leading causes of mortality by sex. The most striking transition in mortality cause over time was the reduction in deaths due to natural disaster and communicable diseases, and the emergence of mortality due to injuries (especially in the context of war) and NCDs. In 1990 and 2005 natural disaster ranked as a leading cause of mortality for adolescents, whereas in 2015 it was no longer a leading cause of death for adolescents. In 2015, war and legal interventions (law enforcement) was the leading cause of death for adolescents of both sexes, representing 27.7% (14.2--38.4) of deaths amongst male 20- to 24-year olds and 7.2% (3.1--10.9) amongst female 20- to 24-year olds. For males, injuries (unintentional injuries, self-harm and violence) were the predominant causes of mortality across adolescence, and communicable diseases an important cause for 10- to 14-year olds. The leading cause of mortality for females included injuries; however, communicable and maternal conditions were also leading causes, with NCDs emerging as an important cause amongst older female adolescents.Table 2Leading contributors to poor health (mortality) for adolescents in the Eastern Mediterranean Region, in 1990, 2005, 2015Top ten causes of mortality in females and malesFemales199020052015RankCauseProportionCauseProportionCauseProportion10--14 years1***Natural disaster**8.0% (3.2--12.6)**Natural disaster**12.8% (7.4--18)**War and legal intervention**9.5% (4.2--14.2)***2*Diarrheal diseases5.8% (4.1--7.8)Typhoid fever5.3% (2.9--8.9)Lower respiratory infect.5.6% (3.6--7.3)*3*Lower respiratory infect.5.7% (3.5--7.4)Lower respiratory infect.4.7% (3.2--6.1)Typhoid fever5.2% (2.9--8.7)*4*Measles5.3% (1.5--12.7)Diarrheal diseases4.6% (3.2--6.7)***Congenital heart4.8% (3.3--6.5)**5*Tuberculosis4.5% (2.2--67)Tuberculosis4.4% (2.5--6.4)****Drowning**4.3% (2.7--5.9)***6***Drowning**4.3% (2.5--6.4)**Drowning**4.1% (2.6--5.8)****Tuberculosis4.0% (2.3--6)*7*Typhoid fever4.3% (2 3--7.5)***Congenital heart3.9% (2.6--5.8)***Diarrheal diseases3.9% (2.6--5.9)*8***Motor vehicle road inj.**3.2% (2.4--4.2)**Motor vehicle road inj.***3.5% (2.8--4.2)***Motor vehicle road inj.**3.6% (2.9--4.5)***9**Hemorrhagic stroke3.1% (2.5--3.9)***Malaria2.8% (0.9--7.2)****Other unintentional**2.7% (1.7--4.1)***10**Congenital heart3.1% (2--5.2)***Measles2.4% (0.6--6.7)Malaria2.6% (0.7--7.6)*15--19 years1***Natural disaster**5.8% (2.2--9.3)**Natural disaster**8.1% (4.4--11.5**War and legal intervention**10.1% (4.4--15.5)***2*Tuberculosis5.8% (3.3--8.7)Maternal hemorrhage5.4% (3.7--7.2)Tuberculosis4.7% (2.8--6.7)*3*Maternal hemorrhage5.5% (3.8--7.7)Tuberculosis5.2% (3.2--7.2)Maternal hemorrhage3.8% (2.3--5.6)*4*Diarrheal diseases4.2% (3--5.7)Maternal hypertension3.6% (2.4--5)****Motor vehicle road inj.**3.5% (2.8--4.4)***5*Maternal hypertension3.8% (2.4--5.7)****Motor vehicle road inj.**3.6% (2.9--4.4)****Maternal hypertension3.4% (2--5.3)*6***Drowning**3.4% (2--5.2)****Diarrheal diseases3.5% (2.4--4.9)****Drowning**3.4% (2--4.8)***7**Ischemic heart disease3.0% (2.5--3.6)*Drowning**3.4% (2--4.7)****Malaria3.3% (1.5--6.3)*8***Motor vehicle road inj.**2.9% (2.3--3.7)**Self-harm**3.4% (2.5--6.3)**Self-harm**2.9% (2.1--6.3)***9***Self-harm**2.9% (1.9--5.3)*Ischemic heart disease2.9% (2.4--3.5)***Diarrheal diseases2.9% (1.9--4.2)*10**Hemorrhagic stroke2.8% (2.3--3.4)***Malaria2.9% (1.5--5.1)***Ischemic heart disease2.8% (2.3--3.5)**20--24 years1*Maternal hemorrhage8.2% (5.8--11)Maternal hemorrhage7.7% (5.7--10.2)****War and legal intervention**7.2% (3.1--10.9)***2*Tuberculosis7.1% (4.4--10.7)Tuberculosis6.2% (4--8.5)Tuberculosis5.9% (3.7--8.1)*3*Maternal hypertension5.6% (3.7----8.2)****Natural disaster**5.9% (3.2--8.5)****Maternal hemorrhage5.6% (3.7--8.1)*4***Natural disaster**4.1% (1.5--6.6)****Maternal hypertension***5.4% (3.8--7.4)***Maternal hypertension5.0% (3.1--7.6)*5*Other maternal disorders3.9% (2.4--5.8)****Motor vehicle road inj.**3.6% (2.9--4.4)*Ischemic heart disease3.6% (3--4.4)**6**Ischemic heart disease3.6% (3--4.3)Ischemic heart disease**3.5% (2.9--4.3)***Motor vehicle road inj.**3.5% (2.9--4.3)***7**Hemorrhagic stroke2.9% (2.4--3.5)*Self-harm***3.3% (2.4--6.2)***Self-harm**3.1% (2.3--6.5)***8***Motor vehicle road inj.**2.8% (2.2--3.7)*Hemorrhagic stroke**2.6% (2.2--3.2)*Other maternal disorders2.9% (1.7--4.5)*9*Diarrheal diseases2.8% (2--3.9)Abortion, miscarriage, ectopic2.3% (1.5--3.3)***Hemorrhagic stroke2.6% (2.1--3.3)**10*Abortion, miscarriage, ectopic2.8% (1.7--4.4)Other maternal disorders2.2% (1.6--3.1)***Cirrhosis other2.2% (1.5--3)**Top ten causes of mortality in females and malesMales199020052015RankCauseProportionCauseProportionCauseProportion10--14 years1***Natural disaster**9.8% (15.1--3.9)**Natural disaster**16.1% (9.4--22.1)**War and legal intervention**12.2% (5.5--18.1)***2***Drowning**8.6% (10.9--6.5)**Drowning**6.4% (5.2--7.7)**Other unintentional**6.9% (4.6--10.1)***3*Lower respiratory infect.5.4% (7.1--3.4)****Motor vehicle road inj.**5.7% (4.8--7)**Drowning**6.4% (5.2--7.9)***4***Motor vehicle road inj.**5.3% (6.3--4.2)**Other unintentional**5.6% (3.6--8.2)**Motor vehicle road inj.**6.0% (4.8--7.5)***5***Pedestrian road inj.**5.3% (6.6--4)**Pedestrian road inj.**5.0% (3.9--6.2)****Lower respiratory infect.4.8% (3.5--6.3)*6*Diarrheal diseases4.1% (6--2.7)Lower respiratory infect.4.2% (3.2--5.5)****Pedestrian road inj.**4.7% (3.6--5.9)***7*Measles3.7% (9.2--1)Typhoid fever4.0% (2.2--6.8)Typhoid fever4.0% (2.1--7)*8***Other unintentional**3.7% (5.4--2.5)****Diarrheal diseases3.1% (1.9--4.7)Diarrheal diseases2.9% (1.8--4.6)*9*Typhoid fever3.6% (6.1--1.9)***Hemorrhagic stroke2.3% (1.9--2.6)Congenital heart2.6% (1.8--3.4)**10**Hemorrhagic stroke3.3% (4.1--2.7)Congenital heart2.2% (1.4--2.9)Hemorrhagic stroke2.2% (1.9--2.6)**15--19 years1***Natural disaster**9.6%(3.8--14.8)**Natural disaster**12.5% (7.2--17.5)**War and legal intervention**27.2% (13.2--37.9)***2***Motor vehicle road inj.**8.9% (6.8--11.8)**Motor vehicle road inj.**9.8% (8.1--12.1)**Other unintentional**8.4% (5--12.5)***3***Drowning**6.7% (4.8--8.9)**Other unintentional**7.9% (5.2--11.3)**Motor vehicle road inj.**8.4% (6.5--10.8)***4***Other unintentional**5.3% (3.5--7.5)**Pedestrian road inj.**5.4% (4.1--6.8)**Drowning**4.0% (3.1--5.2)***5***Pedestrian road inj.**4.7% (2.9--6.2)**Drowning**5.1% (4.3--6.2)**Pedestrian road inj.**4.0% (2.9--5.3)***6***War and legal intervention**4.3% (1.5--9.3)**Motorcyclist road inj.**4.0% (2.9--5.4)**Self-harm**2.9% (2.2--3.7)***7***Self-harm**3.1% (2.4--4)**Self-harm**3.5% (2.8--4.2)**Motorcyclist road inj.**2.8% (1.8--3.9)***8***Motorcyclist road inj.**3.0% (1.8--4.5)**War and legal intervention**3.4% (1.7--5)****Lower respiratory infect.2.3% (1.6--3.1)*9*Lower respiratory infect.3.0% (2--3.8)Lower respiratory infect.2.4% (1.8--3.1)****Physical violence by firearm**2.2% (1.2--3.3)***10**Hemorrhagic stroke2.8% (2.2--3.4)Hemorrhagic stroke2.2% (1.8--2.5)*Other physical violence**1.8% (0.8--2.9)***20--24 years1***Motor vehicle road inj.**9.9% (7.7--12.9)**Motor vehicle road inj.**11.1% (9.4--13.4)**War and legal intervention**27.7% (14.2--38.4)***2***Natural disaster**6.8% (2.7--10.8)**Natural disaster**8.9% (5--12.8)**Motor vehicle road inj.**8.9% (7--11.3)***3***War and legal intervention**5.3% (1.8--11.5)**Other unintentional**6.8% (4.4--10.1)**Other unintentional**6.8% (4--10.3)***4***Pedestrian road inj.**5.0% (3.1--6.5)**Pedestrian road inj.**5.7% (4.4--7)**Pedestrian road inj.**4.2% (3.1--5.4)***5***Other unintentional**5.0% (3.3--7.1)**Self-harm**4.6% (3.8--5.5)**Self-harm**3.8% (3--5)***6***Drowning**5.0% (3.4--6.7)**War and legal intervention**4.3% (2.2--6.4)**Motorcyclist road inj.**2.8% (2--4)***7***Self-harm**4.2% (3.3--5.4)**Motorcyclist road inj.**4.1% (3--5.6)**Drowning**2.8% (2.2--3.6)***8**Tuberculosis3.7% (2.4--5.9)*Drowning**3.7% (3.1--4.4)**Other physical violence**2.6% (1--4)***9***Motorcyclist road inj.**3.1% (1.8--4.7)**Other physical violence**3.0% (1.3--4.1)**Physical violence by firearm**2.4% (1.3--3.6)***10**Ischemic heart disease3.0% (2.5--3.6)Ischemic heart disease2.7% (2.3--3.2)Ischemic heart disease2.3% (1.8--2.9)**Global burden of disease study 2015, Eastern Mediterranean Region, 1990--2015*Italic* defines communicable, maternal, neonatal and nutritional diseases*Bold* defines non-communicable diseases*Bold, italic* defines injuries

YLDs {#Sec5}
----

All-cause YLD rates are similar for males and females in the region, and have seen little improvement since 1990 (e-Figure 1 panel B). The leading causes of YLDs are detailed in Table [3](#Tab3){ref-type="table"}. While the burden of some communicable, maternal, and nutritional disorders has declined, this has largely been offset by an increase in disability due to injury among males and lack of reduction in YLDs from non-communicable disease. From 1990 to 2015, iron deficiency anemia was the leading cause of disability for females aged 10--14 and 15--19 years, and for males aged 10--14 years. NCDs, particularly mental health disorders, migraine, asthma, skin conditions, and musculoskeletal disorders, were major contributors to YLDs for both sexes in 2015. Major depression emerged as the leading cause of morbidity amongst males aged 15--19 (7.0%, uncertainty 4.6--9.9) and 20--24 years (8.0%, uncertainty 5.1--11.7) and for females aged 20--24 years (9.1%, uncertainty 6.2--12.4) in 2015. Among older males, opioid use disorders and war were also important causes of disability.Table 3Leading contributors to poor health (YLDs) for adolescents in the Eastern Mediterranean Region, in 1990, 2005, 2015Top ten causes of years lived with a disability (YLDs) in females and malesFemales199020052015RankCauseProportionCauseProportionCauseProportion10--14 years1*Iron-deficiency anemia15.7% (13.5--17.6)Iron-deficiency anemia16.4% (13.9--18.6)Iron-deficiency anemia16.7% (14.3--18.9)*2**Migraine7.0% (4.4--9.9)Migraine7.5% (4.7--10.7)Migraine7.6% (4.8--10.8)**3**Anxiety disorders6.4% (4.6--8.8)Anxiety disorders6.8% (4.9--9.3)Anxiety disorders7.0% (5--9.5)**4**Asthma5.6% (4.2--7.4)Conduct disorder5.8% (3.3--8.6)Conduct disorder5.9% (3.4--8.8)**5**Conduct disorder5.5% (3.1--8.4)Asthma5.3% (3.9--6.9)Asthma5.7% (4.1--7.6)**6**Major depressive disorder4.1% (2.6--6)Major depressive disorder4.3% (2.7--6.2)Major depressive disorder4.4% (2.8--6.3)**7**Low back pain3.0% (2.3--3.9)Acne vulgaris3.1% (1.7--5.3)Acne vulgaris3.2% (1.7--5.5)**3**Epilepsy2.9% (1.9--3.9)Low back pain3.0% (2.3--4)Low hack pain3.0% (2.3--4)**9**Acne vulgaris2.8% (1.5--4.8)Epilepsy2.8% (2--3.8)Dermatitis2.8% (2.1--3.6)**10**Dermatitis2.5% (1.9--3.3)Dermatitis2.7% (2--3.6)Epilepsy2.6% (1.8--3.7)**15--19 years1*Iron-deficiency anemia10.3% (8.2--12.3)Iron-deficiency anemia10.1% (8.3--12)Iron-deficiency anemia10.0% (8.1--11.9)*2**Major depressive disorder8.0% (5.6--10.9)Major depressive disorder8.1% (5.7--11)Migraine8.3% (5.3--11.9)**3**Migraine7.9% (4.9--11.3)Migraine8.1% (5.1-- 11.4)Major depressive disorder8.3% (5.9--11.2)**4**Anxiety disorders6.8% (5--9.2)Anxiety disorders7.0% (5.2--9.4)Anxiety disorders7.2% (5.3--9.7)**5**Low back pain5.0% (3.8--6.4)Low back pain5.1% (3.9--6.6)Low hack pain5.0% (3.8--6.5)**6**Acne vulgaris3.5% (1.8--5.9)Acne vulgaris3.7% (2--6.3)Acne vulgaris3.9% (2--6.6)**7**Asthma3.4% (2.4--4.4)Other musculoskeletal3.7% (2.6--5.1)Other musculoskeletal3.9% (2.7--5.5)**8**Conduct disorder3.1% (1.8--4.9)Conduct disorder3.2% (1.9--5)Conduct disorder3.3% (1.9--5.1)**9**Other musculoskeletal3.0% (2.1--4.2)Asthma3.2% (2.3--4.2)Asthma3.3% (2.3--4.3)**10**Epilepsy2.2% (1.5--3)Epilepsy2.1% (1.5--2.8)Epilepsy2.0% (1.4--2.8)**20--24 years1*Iron-deficiency anemia10.2% (8.1--12.3)Iron-deficiency anemia9.0% (7.1--11)***Major depressive disorder9.1% (6.2--12.4)**2**Major depressive disorder8.7% (5.9--11.8)Major depressive disorder8.8% (6--12.1)***Iron-deficiency anemia8.9% (7--10.8)*3**Migraine7.8% (4.9--11.4)Migraine8.0% (5--11.6)Migraine8.3% (5.3--12)**4**Anxiety disorders6.0% (4.4--8.2)Anxiety disorders6.2% (4.5--8.5)Anxiety disorders6.4% (4.7--8.6)**5**Low back pain6.0% (4.6--7.7)Low back pain6.1%(4.7--7.9)Low back pain6.1% (4.7--7.9)**6**Other musculoskeletal4.2% (3--5.6)Other musculoskeletal4.9% (3.5--6.6)Other musculoskeletal5.4% (3.9--7.3)**7**Bipolar disorder2.4% (1.6--3.5)Neck pain2.5% (1.7--3.4)Bipolar disorder2.5% (1.7--3.7)**8**Neck pain2.3% (1.5--3.2)Bipolar disorder2.4% (1.6--3.5)Neck pain2.4% (1.6--3.3)**9**Other mental and substance2.2% (1.7--2.8)Other mental and substance2.3% (1.8--2.9)Other mental and substance2.4% (1.9--3.1)**10**Premenstrual syndrome1.9% (1.4--2.6)Premenstrual syndrome1.9% (1.4--2.6)Medication overuse1.9% (1.2--3)**Top ten causes of years lived with a disability (YLDs) in females and malesMales199020052015RankCauseProportionCauseProportionCauseProportion10--14 years1*Iron-deficiency anemia18.9% (16.6--20.9)Iron-deficiency anemia19.4% (17--21.5)Iron-deficiency anemia19.5% (17--21.6)*2**Conduct disorder7.5% (4.7--10.7)Conduct disorder7.9% (5--11.3)Conduct disorder8.1% (5.1--11.5)**3**Asthma5.3% (3.9--6.9)Asthma5.2% (3.8--6.8)Asthma5.1% (3.7--6.8)**4**Anxiety disorders4.0% (2.8--5.5)Anxiety disorders4.2% (3--5.9)Anxiety disorders4.3% (3.1--6.1)**5**Migraine3.3% (2--4.8)Migraine3.5% (2.2--5.2)Migraine3.6% (2.2--5.3)**6**Low back pain2.9% (2.2--3.9)Low back pain3.1% (2.3--4)Low back pain3.0% (23--4.1)**7**Epilepsy2.9% (2--3.9)Major depressive disorder2.9% (1.7--4.5)Major depressive disorder3.0% (1.8--4.6)**8**Major depressive disorder2.7% (1.6--4.3)Acne vulgaris2.8% (1.5--4.7)Acne vulgaris2.9% (1.5--4.9)**9**Acne vulgaris2.5% (1.3--4.2)Epilepsy2.6% (1.8--3.4)Epilepsy2.5% (1.7--3.5)**10**Thalassemias trait2.2% (1.9--2.4)Thalassemias trait2.4% (2.1--2.6)Thalassemias trait2.4% (2.1--2.7)**15--19 years1*Iron-deficiency anemia7.7% (6.2--9.6)***Major depressive disorder6.9% (4.5--9.9)Major depressive disorder7.0% (4.6--9.9)**2**Major depressive disorder6.6% (4.3--9.6)***Iron-deficiency anemia6.8% (5.2--8.6)Iron-deficiency anemia6.5% (5--8.3)*3**Low back pain6.3% (4.9--8.1)Low back pain6.5% (4.9--8.3)Low back pain6.4% (4.8--8.3)**4**Conduct disorder5.7% (3.5--8.3)Conduct disorder6.0% (3.8--8.7)Conduct disorder6.0% (3.7--8.8)**5**Migraine4.9% (3--7.1)Migraine5.2% (3.2--7.5)Migraine5.3% (3.3--7.7)**6**Anxiety disorders4.6% (3.3--6.3)Anxiety disorders4.9% (3.5--6.6)Anxiety disorders4.9% (3.6--6.7)**7**Acne vulgaris3.7% (1.9--6.4)Acne vulgaris4.1% (2.1--6.8)Acne vulgaris4.2% (2.2--7.1)**8**Asthma3.5% (2.6--4.6)Other musculoskeletal3.8% (2.7--5.3)Other musculoskeletal4.0% (2.7--5.6)**9**Other musculoskeletal3.0% (2--4.3)Asthma3.5% (2.5--4.6)Asthma3.3% (2.4--4.5)**10**Epilepsy2.6% (1.9--3.5)Epilepsy2.5% (1.8--3.3)*War and legal intervention**2.7% (1.2--5)***20--24 years1**Major depressive disorder7.7% (4.9--11.4)Major depressive disorder7.9% (5--11.8)Major depressive disorder8.0% (5.1--11.7)**2**Low back pain7.3% (5.7--9.4)Low back pain7.4% (5.7--9.4)Low back pain7.4% (5.7--9.4)**3**Migraine5.7% (3.7--8.1)Migraine5.8% (3.8--8.3)Migraine5.9% (3.8--8.5)**4**Other mental and substance4.2% (3.4--5.3)Opioid use disorders5.1% (3.6--6.8)Other musculoskeletal4.9% (3.5--6.6)**5*Iron-deficiency anemia4.2% (3--5.5)***Other musculoskeletal4.6% (3.3--6.1)Opioid use disorders4.9% (3.5--6.6)**6**Opioid use disorders4.2% (2.9--5.6)Other mental and substance4.4% (3.6--5.5)Other mental and substance4.5% (3.5--5.5)**7**Anxiety disorders3.9% (2.7--5.5)Anxiety disorders4.0% (2.8--5.5)Anxiety disorders4.0% (2.8--5.7)**8***War and legal intervention**3.8% (2--6.1)****Iron-deficiency anemia3.6% (2.6--4.8)****War and legal intervention**3.6% (1.6--6.3)***9**Other musculoskeletal3.5% (2.5--4.8)Neck pain2.5% (1.7--3.5)***Iron-deficiency anemia3.1% (2.2--4.1)*10***Other unintentional inj.**2.3% (2--2.7)*Bipolar disorder2.4% (1.6--3.5)Bipolar disorder2.4% (1.6--3.5)**Global burden of disease study 2015, Eastern Mediterranean Region, 1990--2015*Italic* defines communicable, maternal, neonatal and nutritional diseases*Bold* defines non-communicable diseases*Bold, italic* defines injuries*YLDs* years of life with disability

DALYs {#Sec6}
-----

All-cause DALY rates have declined for females of all ages and 10- to 14-year-old males in the region (e-Figure 1, panel c), largely due to a reduction of communicable, maternal, and nutritional diseases. DALY rates have increased for males aged 15--19 and 20--24 since 1990, largely due to an increased burden of injury. The leading causes of DALYs by age and sex are provided in Table [4](#Tab4){ref-type="table"}. For females, type 1 conditions (nutritional disorders, communicable disease, and maternal disorders) remain important causes of DALYs. However, non-communicable diseases (mental health disorders, migraine, skin conditions, and musculoskeletal disorders) account for more than half of the total disease burden. For males, injuries due to conflict, transport, and other unintentional injuries are the leading causes of DALYs, particularly amongst 15- to 24-year olds.Table 4Leading contributors to poor health (DALYs) for adolescents in the Eastern Mediterranean Region, in 1990, 2005, 2015Top ten causes of disability- adjusted life years (DALYs) in females and malesFemales199020052015RankCauseProportionCauseProportionCauseProportion10--14 years1*Iron-deficiency anemia7.8% (6.1--9.8)Iron-deficiency anemia8.8% (6.9--11)Iron-deficiency anemia9.9% (7.9--12.1)*2***Natural disaster**4.5% (2--6.9)**Natural disaster**7.0% (4--9.8)**War and legal intervention**4.5% (2.3--6.9)***3*Diarrheal diseases3.4% (2.5--4.6)***Migraine4.0% (2.5--5.7)Migraine4.5% (2.8--6.4)**4**Migraine3.4% (2.1--5)Anxiety disorders3.6% (2.5--4.9)Anxiety disorders4.1% (2.9--5.6)**5**Asthma3.3% (2.4--4.3)Asthma3.3% (2.5--4.3)Asthma3.8% (2.7--5)**6**Anxiety disorders3.2% (2.2--4.3)Conduct disorder3.1% (1.8--4.7)Conduct disorder3.5% (2--5.3)**7*Lower respiratory infect.3.0% (1.8--4)Diarrheal diseases2.7% 12--3 .8)***Major depressive disorder2.6 % (1.6--3.7)**8*Measles2.7% (0.8--6.5)Typhoid fever2.5% (1.4--4.2)Lower respiratory infect.2.3% (1.5--3.2)*9**Conduct disorder2.7% (1.5--4.2)Major depressive disorder2.3% (1.4--3.3)Epilepsy2.2% (1.6--2.9)**10*Tuberculosis2.4% (1.3--3.7)Lower respiratory infect.2.2% (1.5--3)Diarrheal diseases2.2% (1.6--3.1)*15--19 years1*Iron-deficiency anemia5.3% (3.9--6.8)Iron-deficiency anemia5.4% (4.1--6.8)Iron-deficiency anemia5.5% (4.2--7.1)*2**Major depressive disorder4.0% (2.7--5.6)*Natural disaster**4.6% (2.7--6.4)**War and legal intervention**5.3% (2.6--8.1)***3**Migraine4.0% (2.4--5.7)Major depressive disorder4.2% (2.9--5.9)Migraine4.6% (2.8--6.6)**4**Anxiety disorders3.4% (2.4--4.7)Migraine4.2% (2.6--6.1)Major depressive disorder4.5% (3.1--6.3)**5***Natural disaster**3.2% (1.4--5.1)*Anxiety disorders3.7% (2.6--4.9)Anxiety disorders3.9% (2.8--5.3)**6*Tuberculosis3.1% (1.9--4.7)***Low back pain2.6% (2--3.5)Low back pain2.7% (2--3.6)**7*Maternal hemorrhage2.7% (1.9--3.9)Tuberculosis2.6% (1.6--3.7)Tuberculosis2.3% (1.4--3.3)*8**Low back pain2.5% (1.9--3.3)***Maternal hemorrhage2.6% (1.8--3.7)***Other musculoskeletal2.3% (1.6--3.1)**9*Diarrheal diseases2.4% (1.8--3.3)***Asthma2.1% (1.5--2.7)Asthma2.2% (1.6--2.9)**10**Asthma2.2% (1.7--2.8)Other musculoskeletal2.0% (1.4--2.8)Acne vulgaris2.2% (1.1--3.8)**20--24 years1*Iron-deficiency anemia5.0% (3.7--6.6)Iron-deficiency anemia4.7% (3.5--6.2)***Major depressive disorder5.0% (3.3--7)**2*Maternal hemorrhage4.2% (3--5.8)***Major depressive disorder4.6% (3--6.5)***Iron-deficiency anemia4.9% (3.6--6.3)*3**Major depressive disorder4.2% (2.8--6)Migraine4.1% (2.6--6.1)Migraine4.5% (2.9--6.7)**4*Tuberculosis3.9% (2.5--5.6)Maternal hemorrhage3.7% (2.6--5.1)****War and legal intervention**3.7% (1.8--5.6)***5**Migraine3.8% (2.4--5.6)*Natural disaster**3.5% (2.1--5)*Anxiety disorders3.5% (2.4--4.8)**6*Maternal hypertension3.1% (2--4.4)***Anxiety disorders3.2% (2.3--4.4)Low back pain3.3% (2.4--4.5)**7**Anxiety disorders2.9% (2--4)***Tuberculosis3.2% (2.1--4.5)***Other musculoskeletal3.1% (2.2--4.2)**8**Low back pain2.9% (2.1--3.8)Low back pain3.2% (2.3--4.2)***Tuberculosis2.9% (1.9--4)*9***Natural disaster**2.3% (0.9--3.7)****Maternal hypertension2.7% (1.9--3.8)Maternal hemorrhage2.6% (1.6--3.8)*10*Other maternal disorders2.1% (1.3--3.1)***Other musculoskeletal2.7% (1.9--3.6)***Maternal hypertension2.4% (1.5--3.7)*Top ten causes of disability- adjusted life years (DALYs) in females and malesMales199020052015RankCauseProportionCauseProportionCauseProportion10--14 years1*Iron-deficiency anemia8.4% (6.5--10.6)Iron-deficiency anemia9.5% (7.4--11.8)Iron-deficiency anemia10.6% (8.4--13)*2***Natural disaster**5.8% (2.4--9.1)**Natural disaster**8.9% (5--12.7)**War and legal intervention**6.2% (2.9--9.5)***3***Drowning**4.9% (3.4--6.3)*Conduct disorder3.9% (2.4--5.8)Conduct disorder**4.4% (2.7--6.5)4**Conduct disorder3.3% (2--5)*Other unintentional**3.6% (2.6--5)**Other unintentional**4.0% (2.8--5.6)***5***Motor vehicle road inj.**3.0% (2.3--4)**Drowning**3.3% (2.6--4.1)*Asthma3.3% (2.5--4.4)**6*Lower respiratory infect.3.0% (2--4.1)***Asthma3.2% (2.4--4.1)*Drowning**2.9% (2.3--3.8)***7**Asthma3.0% (2.3--3.9)*Motor vehicle road inj.**3.0% (2.4--3.7)**Motor vehicle road inj.**2.8% (2.2--3.5)***8***Pedestrian road inj.**3.0% (2.2--3.9)**Pedestrian road inj.**2.6% (2--3.2)*Anxiety disorders2.3% (1.6--3 2)**9***Other unintentional**2.8% (2.2--3.8)****Lower respiratory infect.2.2% (1.6--3)Lower respiratory infect.2.3% (1.6--3.1)*10*Diarrheal diseases2.6% (1.8--3.7)Typhoid fever2.1% (1.1--3.6)****Pedestrian road inj.**2.1% (1.6--2.8)***15--19 years1***Natural disaster**6.0 % (2.5--9.3)**Natural disaster**7.9% (4.4--11.3)**War and legal intervention**17.9% (8.9--25.7)***2***Motor vehicle road inj.**5.3% (4--7.1)**Motor vehicle road inj.**5.9% (4.8--7.5)**Other unintentional**5.9% (3.9--8.3)***3***Other unintentional**4.0% (3--5.4)**Other unintentional**5.6% (3.9--7.7)**Motor vehicle road inj.**5.2% (4.1--6.6)***4***Drowning**4.0% (2.8--5.4)**Pedestrian road inj.**3.2% (2.4--4.1)*Major depressive disorder2.7% (1.7--4.1)**5*Iron-deficiency anemia3.3% (2.4--4.4)****Drowning**3.1% (2.5--3.8)****Iron-deficiency anemia2.5% (1.7--3.5)*6***War and legal intervention**3.2% (1.5--6.2)****Iron-deficiency anemia2.8% (2--3.8)****Drowning**2.5% (1.9--3.2)***7***Pedestrian road inj.**2.8% (1.7--3.7)*Major depressive disorder2.8% (1.7--4.2)*Pedestrian road inj.**2.5% (1.8--3.3)***8**Major depressive disorder2.7% (1.7--4.1)Low back pain2.6% (1.9--3.5)Low back pain2.4% (1.7--3.3)**9**Low back pain2.6% (1.9--3.5)*Motorcyclist road inj.**2.4% (1.7--3.3)*Conduct disorder2.3% (1.4--3.6)**10**Conduct disorder2.3% (1.4--3.6)Conduct disorder2.4% (1.4--3.7)Migraine2.0% (1.2--3)**20--24 years1***Moter vehicle road inj.**6.2% (4.9--8.1)**Motor vehicle road inj.**7.1% (5.8--8.7)**War and legal intervention**19.5% (10--27.7)***2***War and legal intervention**4.7% (2.3--8.7)**Natural disaster**5.9% (3.3--8.5)**Motor vehicle road inj.**5.9% (4.7--7.4)***3***Natural disaster**4.4% (1.8--7)**Other unintentional**5.2% (3.7--7.3)**Other unintentional**5.2% (3.4--7.4)***4***Other unintentional**4.0% (2.9--5.4)**Pedestrian road inj.**3.6% (2.7--4.5)**Pedestrian road inj.**2.8% (2.1--3.5)***5***Pedestrian road inj.**3.1% (1.9--4.2)**War and legal intervention**3.4% (2--4.8)**Major depressive disorder**2.7% (1.7--4.3)***6***Drowning**3.1% (2.1--4.2)*Major depressive disorder2.9% (1.8--4.7)*Low back pain**2.5% (1.8--3.5)***7**Major depressive disorder2.9% (1.8--4.5)*Self-harm**2.9% (2.4--3.5)**Self-harm**2.5% (2--3.2)***8**Low back pain2.8% (2--3.8)Opioid use disorders2.8% (2.2--3.4)Opioid use disorders2.5% (1.9--3.2)**9***Self-harm**2.6% (2.1--3.4)*Low back pain2.7% (1.9--3.7)Migraine2.0% (1.3--3.1)**10*Tuberculosis2.5% (1.6--3.9)****Motorcyclist road inj.**2.6% (1.9--3.6)**Motorcyclist road inj.**1.9% (1.3-2.6)***Global burden of disease study 2015, Eastern Mediterranean Region, 1990--2015*Italic* defines communicable, maternal, neonatal and nutritional diseases*Bold* defines non-communicable diseases*Bold, italic* defines injuries*DALYs* disability-adjusted life-years

There was considerable variation in all-cause and cause-specific DALY rates across countries in the region (e-Figure 2, panels A--C). In all countries in the region, DALY rates are highest among males, and higher among 20- to 24-year olds than other ages in males and females. The highest DALY rates were in countries most affected by recent conflict or insecurity and/or those with the lowest SDI, such as Pakistan (17,483 per 100,000 10--24 years in 2015), Somalia (27,716 DALYs per 100,000 10- to 24-year olds in 2015), Afghanistan (32,068 per 100,000 10- to 24-year olds in 2015) and Syria (33,452 per 100,000 10- to 24-year olds in 2015), with 10- to 24-year olds globally having a DALY rate of 14,557 per 100,000 in 2015. In these countries, injury, particularly due to war and legal intervention was a major contributor to DALYs, particularly amongst males. For example, in Syria over 70% of DALYs to 10--24 year olds were due to injury, with males aged 20--24 experiencing the largest burden. A number of these countries also experience a high burden of nutritional disorders and communicable disease among younger adolescents, in addition to a substantial burden of maternal health problems. Countries with a higher SDI and those less affected by conflict experienced a lower burden of poor health. In these settings DALYs were mostly due to NCDs including mental health disorders, skin conditions, asthma, migraine, and musculoskeletal disorders.

The three countries that had the largest populations of adolescents in the EMR (Pakistan, Iran, and Egypt) had very different disease burdens. Egypt (12,418 DALYs per 100,000 10- to 24-year olds in 2015) and Iran (12,624 DALYs per 100,000 10- to 24-year olds in 2015) has similar low rates of DALYs; however, Iran had a higher burden due to injury (3361 per 100,000 in Iran compared to 1938 per 100,000 in Egypt). Pakistan had a high burden of injury (3367 per 100,000) but more so type I conditions (5252 per 100,000).

e-Figure 2, panels D--F shows the expected DALYs in each country based on the SDI. The most striking finding is that with the reduction of DALYs due to war (which is not expected based on development), there remains a very large burden of poor health for adolescents in the EMR.

Health risks and determinants {#Sec7}
-----------------------------

The prevalence of selected health risks is provided in e-Figure 3. The prevalence of overweight and obesity was highest among countries with a higher SDI in the region, and was generally similar for males and females. Rates of daily tobacco smoking among males aged 10--24 years ranged from 1.9% in Sudan to 18% in Kuwait, but were less than 5% for females in the region. Similarly, the prevalence of binge drinking was higher among males than females at all ages, but was less than 10% for both sexes in most EMR countries. Unmet need for contraception was high among the 11 countries for which data are available (e-Figure 4). More than one third of females who are married or in union have unmet need for contraception in Pakistan, Djibouti, Somalia, Sudan, and Yemen. These countries also have among the highest rates of adolescent birth rates in the region, adolescent fertility the greatest in Somalia (114.7 live births per 1000 females aged 15--19 in 2015). There was also great variation in educational attainment in the EMR region. Low-SDI countries affected by protracted insecurity and conflict have the lowest mean number of years of completed education, most notably for females. Rates of unemployment among 15- to 24-year olds also vary considerably, and were generally higher for females than males.

Discussion {#Sec8}
==========

This study is the first systematic analysis of adolescent health in the EMR. The findings suggest dramatic shifts in the health of adolescents living in the EMR over the past 25 years. Communicable diseases and the health consequences of natural disasters have reduced substantially, but these gains have largely been offset by war and the emergence of NCDs including mental health disorders, unintentional injury, and self-harm. Indeed, adolescents living in Syria, Afghanistan, and Somalia experience amongst the largest burdens of disease and injury of all adolescents globally (Patton et al. [@CR21]). Even with the return of peace and security to this region, adolescents will have a persisting poor health profile that will pose a barrier to socioeconomic growth and development of the EMR (The World Bank [@CR24]).

The substantial reductions in mortality and morbidity due to communicable disease, maternal disorders, and natural disasters in the EMR are likely the result of socioeconomic growth and development, educational participation, and interventions through the health system. Recent wars and civil conflict, however, threaten the foundations on which these gains were made, with the risk of resurgence of many of these conditions. This is in addition to the growing burden of NCDs and injuries. Renewed efforts to consolidate gains made in communicable disease and maternal health will be required. The Lancet Commission described the benefits that can accrue from investments in adolescence. Without these investments, the EMR region risks poor health across adolescence, adulthood, and in the next generation (Patton et al. [@CR21]).

War and legal interventions (deaths due to law enforcement, regardless of their legality) were the leading causes of mortality for adolescents aged 10--24 years of both genders in the EMR. While not all countries in the EMR are affected by conflict, the magnitude of mortality in those countries that are affected signifies this as a priority for the region. It should also be noted, however, that at a population level (all ages combined), war and legal intervention is only the fifth leading cause of mortality in the EMR (GBD 2015 Eastern Mediterranean Region Collaborators and Mokdad [@CR6]). This may reflect competing causes of mortality at other ages, or it may signify that war and legal interventions disproportionately affect adolescents, particularly 20- to 24-year-old males. In addition to the physical injuries and disability that accompany conflict, violence and trauma at this critical developmental stage carry a risk of persisting effects on future mental health and well-being. War and conflict are also likely to result in disruption to quality education, social infrastructure, and community development, which have profound implications for health and well-being across the course of one's life. This may explain why expected DALYs in countries which have experienced large burdens of conflict remain high.

In addition to the health status of adolescents, we explored the burden of risk behavior for future health. Tobacco smoking and high body mass were common risks where interventions during adolescence have the potential to avert later ischemic heart disease, the leading cause of poor health in the region. Of note, estimates of tobacco smoking reported here do not include Sisha smoking which is prevalent in some countries of the EMR and harmful (Maziak et al. [@CR16]). Low rates of education completion in many countries including Afghanistan, Somalia, and Yemen are a major obstacle to growth and future prosperity of this region. High rates of adolescent pregnancy represent an important target for action to improve health and life opportunities for girls and young women. Unmet need for contraception is very high, and is likely to also signify high rates of unmet need for other essential health interventions, particularly for culturally sensitive needs such as sexually transmitted infections and mental health. Given adolescents face barriers in accessing health facilities, there is a need to explore other approaches such as community-based delivery or school health services (Tylee et al. [@CR25]). There is also the need for community-based interventions to address some of the sociocultural barriers that contribute to high unmet need for interventions relating to sexual and reproductive health (Patton et al. [@CR21]).

As over half of the region's adolescents live in Pakistan, Iran, and Egypt (Table [1](#Tab1){ref-type="table"}), a regional response must prioritize these three countries. This is challenging, however, given the different stages of development and the very different needs of adolescents across these countries. For example, the burden of disease experienced by adolescents in Egypt is predominantly caused by NCDs, which require interventions to address the burden of chronic illness and health risks such as tobacco smoking and obesity (Patton et al. [@CR21]). In addition to NCDs, adolescents living in Iran are burdened by injury (particularly relating to transport injury) which requires a suite of inter-sectoral actions (WHO [@CR30]). Adolescents living in Pakistan experience a "multi-burden" profile of disease, with a large burden of communicable, nutritional, and reproductive poor health in addition to NCDs and injury. However, in countries such as Afghanistan, Somalia, and Sudan, adolescents represent almost a third of the country-level population and experience a particularly large and complex burden of disease. It is, therefore, important not to neglect their health needs (or indeed other countries in the EMR).

What this analysis highlights is that unintentional injury, mental health, sexual health, substance use, and self-harm are increasingly important health issues for adolescents in the EMR. While these are health issues common to adolescents globally (Patton et al. [@CR21]), they have typically sat at the margins (if at all) of policy, program, and data collection in EMR, given religious and cultural sensitivities. These findings highlight the need to better align health actions, including data monitoring of sensitive health outcomes, including risks, in this region to these needs.

Our analysis has important limitations. Firstly, there is considerable variation in the availability and quality of primary data for adolescent health. This includes paucity of data for some age groups (particularly 10- to 14-year olds), and for many health outcomes and risks of importance during these important developmental years (Mokdad et al. [@CR19]; Patton et al. [@CR20]; The Global Burden of Disease Child and Adoelscent Health Collaboration [@CR23]). Availability of timely, quality data is likely to be particularly poor in settings of conflict and insecurity, which affects many countries in this region. The poor quality of primary data necessitated the use of modeled estimates, and some of these modeled estimates may have over- or under-estimated the true burden. For example, ischemic heart disease was found to be a leading cause of mortality amongst males aged 20--24 years, a cause of death more commonly associated with adulthood. Premature death due to cardiovascular disease is possible during adolescence, particularly in the context of adolescent obesity which is prevalent in EMR (Franks et al. [@CR4]). This finding may also be an artifact of disease modeling, as ischemic heart disease is the leading cause of mortality in the EMR, and these deaths are modeled to have their onset after 0.1 years of age (GBD 2015 Eastern Mediterranean Region Cardiovascular Disease Collaborators and Mokda [@CR5]; GBD 2015 Eastern Mediterranean Region Collaborators and Mokdad [@CR6]; GBD Mortality and Causes of Death Collaborators [@CR12]). The findings of this study should therefore be interpreted as not only indicating priority areas to address adolescent health in the EMR, but also where data collection efforts should focus. A further limitation is that the broader impacts of armed conflict on adolescent health and well-being, beyond mortality, are not captured by the 2015 GBD study. These include participation in education and employment, as well as the impacts of trauma on adolescent development and wellbeing. Additionally, some important health issues such as female genital cutting/mutilation (common in countries such as Somalia) are not included in GBD 2015 (UNICEF [@CR26]).

There are several regional efforts that may facilitate addressing the needs of adolescents in the EMR. For example, a coalition of youth advocates for health in the EMR has been established (Alaovie et al. [@CR1]). There is a joint UN strategy for youth in the region (IATTTYP [@CR28]). UNICEF has also published guidance around good practice with adolescent and youth programming (UNICEF [@CR27]). This study compliments these efforts, and helps to inform some priority areas for health. For conflict-affected countries, the focus must clearly be on the return of peace and stability and the rebuilding of health, education, and social systems. In doing so, it is important to design services that meet the needs of adolescents. For countries not affected by conflict, health actions include the need to re-orientate health systems to focus on prevention and the growing burden of NCDs. This needs to extend to inter-sectoral actions to address the broader determinants of NCDs and injuries. Without urgent action, there is a risk that profiles of adolescent health will continue to deteriorate with consequences for future population health and wellbeing, productivity, and ultimately the stability of civil society.
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